Atherosclerosis is an inflammatory disorder of arteries. Atherosclerotic plaque, in its early to intermediate stages, is composed largely of lipid-engorged foam cells. These foam cells are derived from the trafficking of monocytes (Mo) into the arterial intima, attracted to the site by chemoattractants. Given that foam cells are derived from the trafficking of Mo, the use of Netrin-1, an Mo chemorepellent, may be useful in limiting Mo accumulation and subsequent plaque formation. To investigate the potential of Netrin-1 for limiting atherosclerosis, we systemically delivered its human (h) cDNA by adeno-associated virus type 8 (AAV8, single-stranded structure) delivery into low-density lipoprotein receptor knockout (LDLRÀ/À) mice and placed the animals on a high cholesterol diet (HCD). Compared with control neomycin resistance (Neo) gene delivery/HCD, hNetrin-1 delivery resulted in a significant reduction in plaque formation, as determined by larger aortic lumen size, thinner intima-media thickness and lower blood velocity than the Neo/HCD control (all statistically significant). Indices of monocyte/macrophage (Mo/MF) accumulation, CD68, integrin, alpha M (ITGAM) and egf-like module containing, mucin-like, hormone receptor-like 1 (EMR-1), were reduced in hNetrin-1/HCD-treated animal's aortas and spleens compared with Neo/HCD-treated animals. Unexpectedly, CD25 and foxp3 (regulatory T cells (Tregs)) in the aorta were strongly upregulated. This is the first time the Mo/MF chemorepellent approach, and specific Netrin-1 gene delivery, has been performed for the reduction of Mo/MF burden and atherosclerosis. In addition, Netrin-1 has never before been linked to altered Treg levels. These data strongly suggest that hNetrin-1 gene delivery can reduce Mo/MF accumulation, inflammation and subsequent plaque formation.
INTRODUCTION
Growing inflammatory cell activity within the vascular wall appears to be firmly established as a critical element for determining the rate of atherosclerotic plaque formation and resulting clinical symptoms in patients. 1 The precise stimulus of the inflammatory cascade in the vessel wall is undetermined, but likely it is associated with the early activation of endothelial cells through sheer stress and other cellular insults. 2 Coupled with injury to the endothelium, concurrent changes in lipid metabolism are linked to the initiation of the inflammatory process in arterial channels. Also concurrent with these events is increased attraction, migration and entrapment of monocytes (Mo) and macrophages (MF) into the arterial intima. Accumulation of other immune cell types accompanies the deposition of Mo and MF.
All this aberrant cell trafficking, altered lipid profile and foam cell formation results in a pathologic physical structure, the atherosclerotic plaque, which can be considered an immune cell tumor. Plaque formation, blocking blood flow and promoting thrombus formation, is the central pathology of atherogenesis. The recruitment of Mo into the inflamed arterial wall is largely due to various chemoattractant molecules, 3, 4 including Mo chemoattractant protein 1, as well as others. 5 Once within the wall, the Mo differentiate into MF, which then utilize a variety of scavenger receptors such as CD36 and lectin-like oxidized low-density lipoprotein receptor-1 to bind and transport modified forms of low-density lipoprotein (LDL) into the cells. This uptake of lipids results in the hallmark cell type of atherosclerosis, the foam cell, and the accumulation of foam cells forms the core parenchyma of atherosclerotic plaque, yet another hallmark of atherosclerosis. 6, 7 As atherosclerosis is a long-term disease, this would seem to necessitate long-term treatments such as gene therapy. Many groups have approached the treatment of atherosclerosis by delivering immune suppressor/anti-inflammatory genes. For example, general immune suppressors interleukin-10 and tumor growth factor-b1 have been shown to inhibit atherosclerosis in mouse models. [8] [9] [10] [11] The manipulation of the immune system may be achieved through cytokines or other genes that selectively inhibit T-helper cell type 1 response or other arms of the immune system, or to increase CD4(+), CD25(+) regulatory T cells (Tregs). 12, 13 Atherogenesis has also been inhibited by altering lipid transport by the delivery of apolipoprotein E or apolipoprotein A1 Milano. [14] [15] [16] There is significant logic in pursuing these approaches; however, as the main cell responsible for the formation of arterial plaque is the Mo, a logical approach might be the use of Mo/MF chemorepellents. This latter approach may yield fewer side effects than full systemic immunosuppressive approach, such as the systemic delivery of interleukin-10 or tumor growth factor-b1. To test this hypothesis, we delivered a prototype Mo/MF repellent, human (h) Netrin-1. 17 Netrin-1 is an Mo/MF chemorepellent, which repulses through the UNC5b receptor, which is expressed on Mo. 17, 18 Here we show hNetrin-1 gene delivery-based inhibition of atherosclerosis in lowdensity lipoprotein receptor knockout (LDLR KO) mice on high cholesterol diet (HCD).
RESULTS

AAV8 delivers hNetrin-1
To test the efficacy of hNetrin-1, we generated an adeno-associated virus (AAV) vector plasmid in which the hNetrin-1 cDNA was expressed from the cytomegalovirus immediate-early promoter as well as one in which the Neomycin resistance gene (Neo) was expressed from the SV40 early promoter, for use as a null, nontherapeutic control. Virus was produced using pDG8 helper and tittered. The structure of the virus vectors and the experimental scheme are shown in Figures 1a and b , respectively. Upon time of harvest, some mice were killed to determine the success of gene delivery by analyzing hNetrin-1 mRNA expression in the aorta using quantitative reverse transcription PCR (qRT-PCR) analysis. This analysis utilized mRNA isolated from three mice aortas from each group, harvested at week 20. Representative results are shown in Figure 2a , and hNetrin-1 was observed to be highly expressed in aortas from AAV/hNetrin-1-injected animals, but not AAV/ Neo-injected or control animals. Figure 2b shows that hNetrin-1 was also observed to be expressed in livers of AAV/hNetrin-1-injected animals relative to AAV/Neo-injected or control animals.
hNetrin-1 delivery inhibits lipid deposition and blood flow velocity Following demonstration of successful transgene delivery (hNetrin-1 expression), we studied the effects of the transgene. Figure 2c shows that hNetrin-1-treated animals had total cholesterol levels comparable with Neo-treated HCD-fed animals. Although hNetrin-1-treated animals trended to be heavier, this did not reach statistical significance (Figure 2d ). The thickness of the smooth muscle layer in the aortas of the three groups was also compared by microscopic-micrometric analysis of cross-section histological sections. As shown in Figure 2e , it was found that the Netrin-1-treated HCD group was not statistically different from control-normal diet (ND) group (Po0.05). However, both were statistically smaller than the Neo-treated HCD group. Figure 3a shows representative unstained aortas from the indicated animal groups. Note that some of the aortas shows significant lipid deposition, white areas, particularly in the AAV/Neo-treated animals, more so than in the negative control (ND-fed animals). Figure 3b shows magnifications of the bracketed areas of the aortas shown in Figure 3a , for easy visualization. As can be seen, AAV/hNetrin-1-treated animals had lower levels of lipid deposition than AAV/ Neo-treated animals, and those from the ND-fed control animals.
We utilized blood flow velocity measurement as a novel technique to quantify atherosclerosis in the mice. Systolic blood flow velocity in the lower abdominal region of the aorta was quantified by high-resolution ultrasound (HRUS) imaging system Vevo 770, with measurements taken on 3-5 animals in each group. Figure 4a shows representative flow velocity images from the analysis in each group of animals. Figure 4b shows the quantified results from five separate measurements on each animal. As shown, the AAV/Neo-treated animals, with the highest lipid deposition, displayed the highest flow velocity, indicating greater luminal obstruction. Moreover, in keeping with visual lipid deposition (Figure 3 ), AAV/hNetrin-1-treated animals had markedly lower flow velocity, statistically similar to that in ND-fed control animals. It was intriguing that the flow velocity data are parallel to the data on atherosclerotic plaque deposits in the aorta.
hNetrin-1 delivery inhibits aortic structural changes associated with atherosclerosis Next, structural changes in the aortas resulting from the various treatments were quantified using HRUS imaging. Multiple measurements were made in each of 3-5 animals from each group and compared. The measurements were made in the same site for the sake of consistency (see Materials and Methods). The cross-sectional area of the lumen of the thoracic region of the aorta was one measurement taken, with five readings from each animal. Figure 5a shows representative captured images from the analysis of the thoracic region of the aorta and Figure 5b shows the quantified results for that region. The AAV/Neo-treated positive control animals displayed the smallest cross-sectional lumen area, as expected. In contrast, AAV/hNetrin-1-treated animals had much larger lumens and this difference was statistically significant (P¼0.026). ND control animals had the largest lumen.
The wall thickness of the thoracic region of the aorta was yet another measurement made, with data from 3-5 animals and five readings from each animal. The AAV/Neo-treated animals displayed the thickest thoracic wall, whereas control mice had much thinner aortic walls (P¼0.034), and the hNetrin-1-treated animals had aortic wall thickness in between the two groups. The aortic wall thickness in the renal region showed similar differences to that seen in the thoracic region, again with AAV/Neo-treated animals having the thickest walls, ND control mice having the thinnest walls (P¼0.032) and the hNetrin-1-treated animals having wall thicknesses in between those two groups.
hNetrin-1 delivery is associated with lower inflammation
Oxidative stress is related to atherosclerosis, which results in the nitration of many proteins, among them are the formation of nitrotyrosine. We therefore analyzed the aortic sections for nitrotyrosine expression by immunohistochemistry. 8, 19 There was a significant increase in nitrotyrosine immunopositivity in the AAV/Neo-treated LDLR KO mice on HCD (vs ND-fed animals) ( Figure 7a ). In sharp contrast, mice injected with AAV/hNetrin-1 showed only very low level of nitrotyrosine staining despite the HCD. The immunopositivity of control mice on ND was very low.
As inflammation appears to play a direct role in atherogenesis, we analyzed the aortas for CD68 expression by immunohistochemistry on tissue from the indicated aortas using anti-CD68 antibody. CD68 is a marker of MF and, thus, can be considered a general marker of macrophage levels as well as of inflammation. The data on the extent of CD68 expression in different groups are shown in Figure 7b . There was a marked increase in CD68 positivity in the LDLR KO mice fed HCD and injected with AAV/Neo control virus. In sharp contrast, the mice injected with AAV/hNetrin-1 showed a much lower level of CD68 staining, despite HCD feeding. ND control mice had very low CD68 levels. Integrin, alpha M (ITGAM) is another MF marker 20 and, again, ITGAM staining (Figure 7c ) was much lower in hNetrin-1-treated animals than in Neo-treated animals, similar to CD68.
Lower levels of inflammation can often be attributed to the presence of CD4(+)/CD25(+)/foxp3(+) T-regulatory cells. 21 Thus, qRT-PCR analysis was carried out utilizing mRNA isolated from three aortas, harvested at week 20 and subjected to qPCR analysis for the expression of foxp3. Representative results are shown in Figure 7d . As can be seen, foxp3 was expressed much greater in aortas from AAV/hNetrin-1-injected animals than that in AAV/Neo-injected animals, both in HCD. This is consistent with higher Treg levels and lower inflammation in the AAV/hNetrin-1-treated animals on HCD. It should also be noted that normal control/ND animals, like AAV/Neo-treated-HCD animals, had low levels of foxp3 expression. To further support these data, we carried out a similar qRT-PCR analysis on CD25 and obtained similar results (Figure 7e ). This is the first observation of a link between Netrin-1 expression and upregulation of Tregs. In addition, shown in Figure 7f , C-reactive protein trended lower in hNetrin-1-plus-HCD animals vs Neo-plus-HCD animals, although not statistically significant. We had hypothesized that the delivery of hNetrin-1 would limit the Mo/MF burden in the aortas. The immunohistochemical analyses of aorta (Figures 7b and c) in fact show this phenomenon. However, we wished to further support this conclusion by qRT-PCR analysis. Because of limited amount of aortic tissues, we utilized spleen as a surrogate organ. qRT-PCR analysis was carried out utilizing mRNA isolated from three spleens from each group at week 20 for the expression of MF markers CD86, ITGAM and EMR-1. Representative results are shown in Figures 8a-c , and, as can be seen, all three MF markers were expressed in much greater amounts in spleens from AAV/Neo-injected animals than the hNetrin-1-injected animals. This is fully consistent with lower inflammation and less MF accumulation in the AAV/hNetrin-1-treated animals on HCD. It should also be noted that normal control/ND animals, like AAV/hNetrin-1-treated-HCD animals, had low MF levels as well.
DISCUSSION
This study shows, for the first time, that hNetrin-1 delivery by tail vein injection with AAV8, which targets vascular smooth muscle cells, 22 is able to inhibit atherogenesis in LDLR KO mice on HCD. Further, supporting our original aim and hypothesis, the Mo load in the aorta and spleen in hNetrin-1-treated aortas was lower than that in Neo control-treated animals. Being a chemorepellent, Netrin-1 has a very different anti-inflammatory mechanism of action than genes such as interleukin-10 and tumor growth factor-b1, among previously studied genes used to inhibit atherosclerosis and inflammation in animal models.
Netrin-1 appears to have a plethora of functions. Its major function may be in brain embryogenesis by functioning as an axon attractant molecule involved in the generation of the normal neuronal lattice development. [23] [24] [25] As with Mo/MF, it is a chemorepellent for oligodendrocyte precursor cells in the embryonic spine, as well as trochlear motor axons. However, it is a chemoattractant for certain other axons. Yet, another function of Netrin-1, as expressed in endothelial capillary tip cells, is in the formation of the developing capillary tree, somewhat similar to axon guidance, during embryogenesis. 24, 26, 27 It may also mildly promote the development of microvessels in the brain by direct AAV2/Netrin-1 gene injection into the brain. 28 Moreover, Netrin-1 may also protect the brain by limiting leukocyte migration and invasion. 17 However, Netrin-1 also has additional activities in the vasculature as well as it appears to inhibit leukocyte adhesion to endothelial cells by downregulating Mo chemoattractant protein 1, thereby providing yet another mechanism for Netrin-1's ability to lower monocyte/macrophage accumulation in arteries. 29 Netrin-1's phenotype is yet even more complicated as it is believed to affect smooth muscle cell migration and proliferation, 30, 31 features associated with atherogenesis.
Most importantly, for this study our main interest was Netrin-1's phenotype as a leukocyte (Mo/MF) repellent. 17 The receptor of Netrin-1 is UNC5b and is expressed on many leukocytes. Netrin-1 is also expressed to some extent on endothelial cells. Our approach was to augment the natural level of expression in the aorta, and thus prevent migration of Mo/MF. As there is only a very limited neuronal component in arteries, the predominant role of Netrin-1 should be its Mo/MF/leukocyte chemorepellent phenotype. The studies in Figures 7 and 8 strongly suggest that this beneficial phenotype was active owing to the gene delivery. Moreover, we found no evidence of vascular smooth muscle proliferation. In addition to its many listed abilities and functions, this study has identified yet another important function for Netrin-1, that being its ability to upregulate Treg numbers. As shown in Figures 7d and e, both CD25 and foxp3 were dramatically upregulated in hNetrin-1-treated aortas. A Netrin-1-Treg connection has never been reported before and clearly this is an important phenotype as Tregs are associated with lower atherosclerosis. 32 The ability of Netrin-1 to limit the development of atherosclerosis shown here suggests that this generalized approach, delivery of Mo/MF repellent genes, can be a successful treatment approach for atherosclerosis. This success also suggests that AAV8/Netrin-1 delivery be assayed at a higher stringency of efficacy, for its ability to reverse established atherosclerosis. Although we found no significant adverse reactions or detrimental histological effects from Netrin-1 delivery, there are a variety of other Mo repellents that might also be tried, which might have higher efficacy than Netrin-1. One example is Eotaxin-3. 33 However, while Eotaxin-3 is an Mo repellent, it is also an eosinophil attractant. There is a significant chance that all of the Mo repellents have more than one phenotype as does Netrin-1 (Treg upregulation among others) and Eotaxin-3 (eosinophil attraction), which can complicate any prediction of therapeutic efficacy. Thus, each must be analyzed for efficacy in the setting of the atherosclerotic prone aorta.
MATERIALS AND METHODS
Generation of recombinant pdl3-97/CMV/hNetrin-1 virus particles hNetrin-1 cDNA was purchased from Open Biosystems (Huntsville, AL, USA) and cloned into BglII and XhoI site, just downstream of the cytomegalovirus immediate-early promoter in the gutted AAV vector plasmid dl3-97 (single-stranded structure). The generation of AAV/Neo virus has been described earlier. 34 The virus stocks were generated and tittered by dot-blot hybridization as described previously. 34 The titers were calculated to be about 1Â10 9 encapsidated genomes per ml (eg ml À1 ).
Animal treatments
LDLR KO mice (B6;129S7-Ldlr tm1Her /J) were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Two groups of male mice, composed of eight animals each and weighing 16-20 g, approximately 12 weeks old, were injected with AAV/Neo or AAV/hNetrin-1 virus at a titer of 1Â10 9 eg ml À1 via tail vein injections of 200 ml virus per mouse, followed by two booster injections at an interval of 1 week each. Significant humoral response in dogs against AAV8 takes about 3 weeks. 34 The animals were started on HCD of 4% cholesterol and 10% Coco butter diet (Harlan Teklad, Madison, WI, USA) on the day of first injection. Mice fed normal chow diet were included as 
High-resolution ultrasound imaging
Ultrasound imaging was carried out using the Vevo 770 High-Resolution Imaging system (Visualsonics, Toronto, Canada) with an RMV 707B transducer having a center frequency of 30 MHz. Animal preparation was carried out as described earlier. 35, 36 Briefly, each mouse was anesthetized using 1.5% isoflurane (Isothesia; Abbot Laboratories, Chicago, IL, USA) with oxygen and laid supine on a thermostatically heated platform with all legs taped to electrocardiography electrodes for cardiac function monitoring. Abdominal hair was removed with a shaver and a chemical hair remover (Church & Dwight Co., Inc., NJ, USA) and a pre-warmed US gel (Medline Industries Inc., Mundelein, IL, USA) was spread over the skin as a coupling medium for the transducer. Two levels of the vessel were visualized: thoracic region-below the aortic arches to the diaphragm and the renal region-the upper abdominal region to the iliac bifurcation. Image acquisition was started on B-mode, in which a long axis view was used to visualize the length of the aorta. Next, the scanhead probe was turned 901 for a short-axis view to visualize the crosssectional area of the aorta. Individual frames and cine loops (300 frames) were acquired at all levels of the aorta both in long and short-axis view and recorded at distances of 1 mm throughout the length of the aorta. For the measurement of flow velocity, orientation of the abdominal aorta on ultrasound was accomplished by tilting the platform and the head of mouse down with the transducer probe toward the feet and tail of the mouse. This positioning ensured the Doppler angle to be less than 601 for accurate measurements of blood flow velocity in the pulse-wave Doppler mode within the abdominal aorta. Measurements and data analysis were performed off-line using the customized version of Vevo770 Analytical Software from both the longitudinal and transverse images. The complete imaging for each mouse lasted for about 25-30 min.
Tissue sampling and processing
At 20 weeks after first injection of virus and on HCD, mice were euthanized by CO 2 exposure and exsanguinations to collect blood. Entire aorta including the aortic arches, thoracic and abdominal aortas was removed as described earlier. 8 The aorta was flushed with saline solution and fixed in 10% neutral-buffered formalin (Sigma, St Louis, MO, USA). After 24 h, the fixed tissue was used for paraffin embedding and sectioning for immunohistochemistry analysis. Animals from each group were also killed and their aorta, liver, heart, kidney and spleen were frozen in liquid nitrogen and stored in À80 1C for RNA isolation and real-time qRT-PCR analyses.
Measurement of plasma cholesterol
Plasma levels of total cholesterol for AAV8/hNetrin-1 and AAV8/Neo mice were measured by VetScan VS2 (Abaxis, Union City, CA, USA) at the Veterans Animal Laboratory (VAMU).
Measurement of smooth muscle layer
Representative histology slides of cross-sections of three aortas from each of the three animal groups were digitally scanned using an Aperio Technologies (Vista, CA, USA) and the thickness of the smooth muscle layers were measured (at least five measurements per aorta) using the ruler function in the Aperio ImageScope software.
hNetrin-1 and foxp3 gene expression analysis using real-time qRT-PCR Total RNA from the aorta, liver and spleen of three mice was extracted with TRIzol extraction (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized using random hexamer primers and RNase H-reverse transcriptase (Invitrogen). To further investigate the hNetrin-1 (sense primer: 5¢-CCCTGCATAAAGATCCCTGT-3¢; antisense primer: 5¢-TGC AGTAGGAATCGCAGTCTT-3¢); mfoxP3 (sense primer: 5¢-TCAGGAGCCCA CCAGTACA-3¢; antisense primer: 5¢-TCTGAAGGCAGAGTCAGGAGA-3¢); mCD68 (sense primer: 5¢-GACCTACATCAGAGCCCGAGT-3¢; antisense primer: 5¢-CGCCATGAATGTCCACTG-3¢); mCD25 (sense primer: 5¢-CCAAC ACAGTCTATGCACCAA-3¢; antisense primer: 5¢-AGATTCTCTTGGAATCTTC ATGTTC-3¢); mITGAM (sense primer: 5¢-CAATAGCCAGCCTCAGTGC-3¢; antisense primer: 5¢-GAGCCCAGGGGAGAAGTG-3¢), and mEMR-1 (sense primer: 5¢-CCTGGACGAATCCTGTGAAG-3¢; antisense primer: 5¢-GGTGGGA CCACAGAGAGTTG-3¢) and C-reactive protein (sense primer: 5¢-TCAGCTTC TCTCGGACTTTTG-3¢; antisense primer: 5¢-AGGTGTTCAGTGGCTTCTT TG-3¢) mRNA expression, qRT-PCR was performed using the Applied Biosystems Fast 7900HT real-time PCR system (Applied Biosystems, Foster City, 
